01177.HK
Sino Biopharmaceutical Limited
HKSE · Healthcare · Biotechnology · HK
HKD 4.85
−0.10%Jul 10, 2026, 19:44 UTC
AI² Robotics raised about $735 million in a fresh financing round, pushing its valuation to about $2.8 billion.
Jul 9, 2026, 06:41 UTC
Sino Biopharmaceutical announced licensing agreements with GlaxoSmithKline for two approved respiratory products Trelegy and Anoro in China.
Source:Jul 7, 2026, 22:06 UTC
China Biologic Pharmaceutical (Sino Biopharmaceutical) entered into an exclusive license agreement with AstraZeneca for TQC3721, granting AstraZeneca exclusive rights outside China, with upfront payment of $200 million and up to $1.9 billion in milestones plus tiered royalties.
Jul 4, 2026, 11:52 UTC
Hong Kong-listed companies, led by Tencent Holdings, AIA Group, and Xiaomi Corporation, have conducted share buybacks totaling over 900 billion Hong Kong dollars year-to-date, with June 2026 reaching a monthly record of over 300 billion Hong Kong dollars.
Jun 12, 2026, 07:26 UTC
Chia Tai Tianqing and Shionogi's drug Symproic (naldemedine) was approved for marketing in China by the NMPA for opioid-induced constipation.
Source:
← PreviousPage 2